H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aptose Biosciences (APTO – Research Report) today and set a price target of $2.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising preliminary results from Aptose Biosciences’ TUSCANY trial. The trial is testing a triplet therapy for acute myeloid leukemia (AML) using tuspetinib, venetoclax, and azacitidine. Early data shows that the combination therapy is safe and effective, with no significant adverse effects observed in the participants at the initial dosage level.
In particular, the trial demonstrated complete remissions in two patients with FLT3-WT mutations and a notable response in a patient with TP53 mutations, which is significant given the poor prognosis generally associated with these mutations. Additionally, the predictable pharmacokinetics of tuspetinib in the combination therapy setting further supports the potential for consistent dosing without the need for adjustments. Given these encouraging results and the ongoing patient enrollment, Pantginis anticipates future updates will continue to be positive, supporting the Buy rating.
Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Esperion, and Viking Therapeutics. According to TipRanks, Pantginis has an average return of -4.1% and a 28.96% success rate on recommended stocks.